# Cabozantinib in Advanced Salivary Gland Cancer Patients

> **NCT03729297** · PHASE2 · TERMINATED · sponsor: **Radboud University Medical Center** · enrollment: 25 (actual)

## Conditions studied

- Salivary Gland Cancer

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT03729297
- **Lead sponsor:** Radboud University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-05
- **Primary completion:** 2019-11-06
- **Final completion:** 2019-11-06
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** safety issues
- **Last updated:** 2021-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03729297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03729297, "Cabozantinib in Advanced Salivary Gland Cancer Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03729297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*